Plasma microRNA patterns linked to worse outcomes in coronary artery disease
Official title: Circulating microRNAs and Adverse Cardiovascular Outcomes in Patients With Coronary Artery Disease
Run by National Taiwan University Hospital · NCT03635255 · Data updated 2026-11-12
This project will see if specific microRNAs in blood can help predict future heart attacks or other serious heart-related events in people with coronary artery disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 460 (estimated) |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Status | Recruiting |
| Started | September 24, 2019 |
| Main results expected | June 30, 2027 |
| Study ends | July 31, 2027 |
| Registry record updated | July 17, 2025 |
| Trial ID | NCT03635255 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 20 with a history of coronary artery disease or other cardiovascular disease (such as peripheral vascular disease) who can attend visits at National Taiwan University Hospital are the intended participants.
✕Probably not a fit
People without established CAD, or those with exclusion conditions such as significant valvular or congenital heart disease, active cancer, or on immunosuppressive therapy, are unlikely to benefit and participants should not expect direct therapeutic benefit from this observational project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will search for circulating microRNA patterns in plasma that correlate with future adverse cardiovascular events and death among patients with established coronary artery disease. Investigators will use next-generation RNA sequencing (RNASeq) on plasma samples to identify candidate miRNAs, then validate top candidates in a larger independent cohort of CAD patients. Parallel laboratory experiments will test selected miRNAs in human aortic endothelial cells to explore possible mechanisms linking these miRNAs to endothelial dysfunction. The goal is to develop a plasma miRNA signature that could serve as a non-invasive prognostic tool for risk stratification in CAD.
Why it matters
Potential benefit: If successful, a blood test measuring specific miRNAs could help doctors identify which CAD patients face higher risk of future adverse cardiovascular events and tailor preventive care.
How similar studies have gone: Several prior studies have reported promising links between circulating miRNAs and cardiovascular risk, but no widely adopted clinical miRNA test for CAD risk prediction has yet been established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female older than 20 years old. 2. Have a history of cardiovascular disease (including coronary heart disease, or peripheral vascular disease) Exclusion Criteria: Significant valvular or congenital heart disease, cancer, immunosuppressive therapy, or other conditions or treatment your physician thinks you have
Where it's running
-
Ntuh
Taipei, Taiwan Recruiting
Study contacts
- Principal investigator: Chau chung Wu, PhD — National Taiwan University Hospital
- Study coordinator: Chau chung Wu, PhD
- Email: Chauchungwu@ntu.edu.tw
- Phone: 02-23123456
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Monitoring low-grade gliomas using blood samples
This study is testing if analyzing blood samples can help monitor patients with low-grade brain tumors for signs of recurrence better than current MRI methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.